Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs

Abstract

The platelet P2Y₁₂ antagonists are widely used, usually in combination with aspirin, to prevent atherothrombotic events in patients with acute coronary syndromes during percutaneous coronary intervention and after placement of arterial stents. Inhibition by clopidogrel or prasugrel lasts for the lifetime of the affected platelets and platelet haemostatic function gradually recovers after stopping the drug, as new unaffected platelets are formed. The optimal durations for dual antiplatelet therapy are prescribed by clinical guidelines. Continuation beyond the recommended duration is associated with an increased mortality, mainly associated with major bleeding. Fear of a ‘rebound’ of prothrombotic platelet activity on stopping the drug has provoked much discussion and many studies. However, review of the available literature reveals no evidence for production of hyper-reactive platelets after cessation of clopidogrel in patients who are stable. Any increase in acute coronary and other vascular events after stopping seems most likely therefore to be due to premature discontinuation or disruption of treatment while thrombotic risk is still high. No difference in rebound was found with the newer P2Y₁₂ inhibitors, although ticagrelor and prasugrel are more potent platelet inhibitors than clopidogrel. Recent randomized controlled trials confirm it is safe to stop the thienopyridine and continue with aspirin alone in most patients after the duration of treatment recommended by the guidelines. Decisions on when to stop therapy in individuals, however, remain challenging and there is a growing rationale for platelet testing to assist clinical judgement in certain situations such as patients stopping dual antiplatelet therapy before surgery or in individuals at highest bleeding or thrombotic risk.

Keywords

antiplatelet therapy cessation clopidogrel platelet activation rebound

Background

Medical therapy to reduce platelet activation is a mainstay in prevention of atherothrombotic events in cardiovascular disease. For many years aspirin was the drug of choice, but randomized controlled trials from the 1990s onwards demonstrated the efficacy of clopidogrel in reduction of major acute coronary and cerebrovascular events and vascular deaths [CAPRIE Steering Committee, 1996]. Clopidogrel in combination with aspirin improved outcomes after acute coronary syndrome (ACS), and after percutaneous coronary intervention (PCI) with or without placement of stents [Bhatt et al. 2006; COMMIT collaborative group 2005; Steinhubl et al. 2002; Yusuf et al. 2001].

Two newer P2Y₁₂ inhibitors are in clinical use. Prasugrel, another irreversible thienopyridine inhibitor [Wiviott et al. 2007], and ticagrelor, a reversible, noncompetitive inhibitor [Wallentin et al. 2009], are now preferred over clopidogrel for acute myocardial infarction for their more rapid and more potent antiplatelet action [Windecker et al. 2014]. However, the association with higher bleeding risk, contraindication in certain categories of patient, and higher cost, mean that clopidogrel is still widely used throughout the world, and following PCI in stable coronary artery disease. For the purposes of this review I will concentrate on clopidogrel.

Action of clopidogrel

Clopidogrel is a prodrug of the thienopyridine class. Conversion to the active metabolite in the liver is dependent on cytochrome P450 isoforms including CYP3A and CYP2C19. There is well recognized variability in responsiveness to clopidogrel, which is at least partly attributable to polymorphisms of these genes [Simon et al. 2009], as well as to drug interactions and adherence to treatment. The main therapeutic target for the active molecule is the platelet P2Y₁₂ receptor for adenosine diphosphate (ADP). Through a Gi-coupled signalling pathway, receptor occupancy induces activation of the αIIb β3 integrin receptor (also known as glycoprotein IIb–IIIa), exposing the receptor for fibrinogen and resulting in platelet aggregate formation [Braun et al. 2007; Schror, 1998]. Inhibition of the P2Y₁₂ is irreversible and so, as with aspirin blockade of cyclooxygenase, this pathway of activation is inhibited for the lifetime of the platelets [Schror, 1998]. Function gradually recovers after stopping the drug because of new, unaffected platelets being produced from megakaryocytes, while ageing platelets are gradually removed. Normal platelet lifespan is 7–10 days, but disease and ageing may influence turnover times and therefore affect the time to recovery of platelet function after a single antiplatelet dose.

Duration of dual antiplatelet therapy

Evidence-based, national and international clinical guidelines prescribe the optimum durations for antiplatelet therapy, and these have evolved considerably over the past decade as more trial results emerge [Jneid et al. 2012; Windecker et al. 2014]. The European Society of Cardiology [Windecker et al. 2014] currently states that after acute myocardial infarction, ST-elevation myocardial infarction or non-ST-elevation myocardial infarction, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y₁₂ inhibitor be continued for 12 months after the acute event; whereas for patients with stable coronary artery disease who receive PCI and a drug-eluting stent (DES), clopidogrel is recommended for 6 months, and for a minimum of 1 month after placement of a bare metal stent. It is usually recommended that patients continue on aspirin for life, unless contraindicated, for example by drug intolerance or bleeding.

Because of the pivotal role of platelets in haemostasis and thrombosis, maintenance of the balance between inhibition and activation is essential. Thus, all antithrombotic agents introduced to date carry the side effect of increased bleeding risk. As the thrombotic risk diminishes over time, for example after successful PCI to unblock the diseased coronary artery, or healing of the vessel wall after placement of stents, the risk of mortality from bleeding becomes disproportionately higher with continued use of DAPT. However, the European guidelines [Windecker et al. 2014] also state that a longer duration can be used in those at high ischaemic risk and low bleeding risk, and a shorter duration in people at lower risk of recurrence or higher bleeding risk. In addition, the need may arise to withdraw antiplatelet drugs earlier than recommended, before surgery for example, or if there is intolerance to the drug, or bleeding events.

What happens clinically on stopping clopidogrel?

The publication of a series of case reports and retrospective studies sounded the alarm over an apparently increased rate of ischaemic events in the period after withdrawal of clopidogrel [Ong et al. 2005; Pfisterer et al. 2006; Ho et al. 2008, 2010]. Ho and colleagues [Ho et al. 2008] reported a clustering of adverse events in patients with previous ACS in the first 90 days after stopping clopidogrel. Despite the observational and retrospective nature of these studies, an ‘Advisory’ statement was issued on premature stopping of DAPT [Grines et al. 2007] (see Gaglia and Waksman for systematic review) [Gaglia and Waksman, 2011].

What happens to platelets when clopidogrel is withdrawn?

These studies provoked discussion of a ‘rebound’ in platelet activity. The theory was proposed that suppression by clopidogrel might lead to a biological adaptation of platelets or megakaryocytes, conferring enhanced sensitivity to ADP or other stimuli. Such a change would manifest itself after cessation of the drug and recovery of a noninhibited, hyperactive platelet population [Lordkipanidzé et al. 2009; Sambu et al. 2011a]. This gave rise to some small studies that claimed to find a rebound of platelet responsiveness at varying times after stopping clopidogrel treatment.

An observational study of 28 patients with coronary stent implantation, who had been treated with clopidogrel for 12 months, found that ADP-stimulated platelet aggregation was increased at 2 weeks after withdrawal of clopidogrel compared with on-treatment levels, and remained elevated at 6 weeks, as would be expected [Diehl et al. 2011]. However, on testing at 17 weeks after stopping, aggregation was lower than at the earlier time points, and was now no different from that in a group of untreated stable CAD controls.

Mylotte and colleagues (2011) studied 32 patients with DES [Mylotte et al. 2011]. Between on-treatment values and the sample taken at 1 week following withdrawal, there was an increase in aggregation response to a range of doses of ADP, epinephrine and thrombin-receptor-activating peptide (TRAP), but not arachidonic acid. There was a further increase in aggregation induced by the lower, but not higher, doses of ADP at 1 month. By 3 months after cessation, however, aggregation with ADP and epinephrine had decreased, returning to levels similar to those found at 7 days, and this was interpreted as a transient rebound effect occurring at 1 month post cessation.

The prospective CESSATION study enrolled 28 patients who stopped clopidogrel therapy 1 year following insertion of a DES. Using the more unusual technique of thromboelastography platelet mapping (short TEG), there was gradual recovery of ADP-induced aggregation up to 1 week, but levels remained similar at 2 and 4 weeks, and so no evidence was found for a rebound in ADP pathways of aggregation [Sambu et al. 2011b].

Thirty-seven patients with clinically stable coronary artery disease who had been taking clopidogrel and aspirin (for varying lengths of time) were compared with a control group of patients with stable CAD who were not taking clopidogrel [Lordkipanidzé et al. 2014]. There were no differences in the Verify Now P2Y₁₂ test, but there was a difference in ADP-stimulated aggregation between the clopidogrel and control groups at 7 and 28 days after stopping. Difficulties in comparing these two groups directly include the considerable individual variability in platelet response, and the reasons for being prescribed clopidogrel or not, which most likely include severity of arterial disease and the estimated thrombotic and bleeding risk.

In contrast, in a study of 200 patients who had taken clopidogrel for 12 months after stenting, there was no evidence for rebound [Djukanovic et al. 2011]. Although again there was no pretreatment test, platelet aggregation by a whole blood multielectrode impedance assay (Multiplate analyzer, Roche Diagnostics GmbH, Mannheim, Germany) merely reached a plateau around 10 days after stopping and was not significantly different at 45 or 90 days.

However, as none of these studies included a pretreatment baseline measurement, it was not possible to say whether platelet responsiveness was merely returning to pretreatment levels.

Platelet studies with a pretreatment baseline

Several prospective studies have been performed that included detailed platelet function analysis at a pretreatment baseline as well as on treatment, and with follow up for at least a month after stopping clopidogrel. In a placebo-controlled crossover study of 15 healthy subjects who took clopidogrel plus aspirin or placebo plus aspirin for 7 days each, a comprehensive range of platelet measurements was made. These comprised activation markers GPIIb/IIIa and P selectin by flow cytometry, aggregometry in platelet-rich plasma and in whole blood, all with a range of doses of ADP and other agonists, counting of the immature platelet fraction, and soluble CD40 ligand assay. Once platelet function had recovered, by around 8 days after stopping, there was no further increase in stimulated platelet aggregation or activation markers and no significant differences in any of the tests at 11, 15 or 45 days post cessation compared with baseline [Frelinger et al. 2010]. These data showed conclusively that a short-term course of clopidogrel did not increase regeneration nor alter the reactivity of newly produced platelets, at least in healthy subjects.

In a prospective, double-blind placebo-controlled trial, Ford and colleagues randomized 171 patients with stable coronary artery disease or peripheral arterial disease to 28 days of clopidogrel (75 mg) or placebo [Ford et al. 2014]. Patients continued to take their 75 mg daily aspirin therapy throughout the study. A range of platelet tests was carried out at pretreatment baseline, on treatment (just before stopping clopidogrel or placebo), and at 7, 14 and 28 days after stopping. ADP-stimulated platelet aggregation (5 and 10 micromolar ADP), platelet activation markers by flow cytometry, Verify Now P2Y₁₂ and VASP-P were all significantly lower on clopidogrel treatment compared with baseline, showing appropriate responses to the drug. Unstimulated markers of platelet activation were unchanged. Values returned to baseline levels by 7 days after discontinuation. Apart from the on-treatment measurements, there were no statistically significant differences between those taking clopidogrel or placebo at any of the follow-up timepoints. Furthermore, there was no evidence for a treatment–time interaction in any of the statistical models, thereby confirming that platelet responsiveness remained stable over time after stopping clopidogrel [Ford et al. 2014].

Two studies used the approach of comparing the recovery of platelet activity in patients who were allocated to abrupt cessation of clopidogrel or to a tapering regimen at the planned completion of their post-stent treatment, with the aim of attenuating any rebound. Neither study found any evidence for a difference in platelet activity after complete cessation [Sibbing et al. 2010; Yedidya et al. 2012].

In summary, in studies with adequate numbers, baseline pretreatment measurements and inclusion of a placebo arm, there has been no evidence for a rebound of platelet responsiveness to ADP after stopping clopidogrel. Instead, these studies show a gradual return to original levels of platelet activation and responsiveness. It is unlikely that any rebound effect would be missed in a 30-day follow up as this is more than adequate for a complete turnover of the platelet population. Furthermore, most of the reported excess of thrombotic events occurs within the first 30 days of stopping [Lemesle et al. 2011]. It has also been argued that increased sensitivity of the P2Y₁₂ receptor may develop over longer-term therapy. However, the incidence of post-clopidogrel thrombotic events is highest in patients who discontinued the drug within 1 month of commencing [Lemesle et al. 2011], a finding more consistent with discontinuation before healing of the arteries was complete.

Most of the controlled laboratory studies selected patients with stable coronary artery disease, and it could be argued that a greater effect might be seen in patients with ACS or DES as they are at higher thrombotic risk. Patients with acute events would unfortunately be more difficult to study rigorously because of the expected long interval between pretreatment sample and stopping clopidogrel. Caution should of course be exercised in extrapolating the results to patients with a recent acute event.

Could there be adaptation of other platelet pathways to clopidogrel?

Reflecting the vital function of haemostasis and thrombus formation, platelets carry many different surface receptors that recognize various stimulatory agonists, and several signalling pathways for activation. As well as the established target of P2Y₁₂ it is apparent that clopidogrel may inhibit aggregation stimulated by other agonists, including arachidonic acid and TRAP [Ford et al. 2013]. Some studies have found that, although there was no rebound effect on ADP pathways of activation or aggregation, the ‘aspirin-specific’ tests, that is, using arachidonic acid as platelet stimulus, appeared less inhibited after stopping clopidogrel but maintaining the aspirin dose [Djukanovic et al. 2014; Hobson et al. 2009, Sambu et al. 2011b]. However, detection appears to be method dependent, as it is not seen with light transmission aggregometry [Ford et al. 2013, 2014; Frelinger et al. 2010], and Good and colleagues have recently shown that there is no additional suppression of thromboxane B2 production when clopidogrel is added to aspirin therapy [Good et al. 2015]. Nevertheless, such synergistic effects probably contribute to the efficacy of dual compared with single antiplatelet therapy.

Reactive inflammation following cessation of clopidogrel has also been proffered as an explanation for an increase in major acute coronary events (MACE) [Angiolillo et al. 2006]. The results are conflicting, however, and are likely to reflect changes in disease state rather than an association with stopping clopidogrel [Sambu et al. 2011a; Wykrzykowska et al. 2009]. It is unclear in any case whether clopidogrel therapy directly affects any inflammatory markers, although, in common with aspirin, appearing to be associated with lower C-reactive protein [Woodward et al. 2004; Husted et al. 2010].

Despite lacking a nucleus, platelets contain the translational mechanisms needed to manufacture proteins [Weyrich et al. 1998], and so an adaptation response of either megakaryocytes or platelets to chronic antiplatelet therapy is not implausible [Lordkipanidzé et al. 2009]. However, there is no evidence to support any prothrombotic changes in receptor number or signalling capacity of platelets in the weeks after antiplatelet therapy in humans, and in any case this would not explain why any such changes were not detectable by the range of functional tests employed in the controlled research studies.

Newer P2Y₁₂ inhibitors and platelet activity

Ticagrelor (a reversible inhibitor) and prasugrel induce more potent inhibition of platelet function than clopidogrel [Storey et al. 2011] and, in the case of prasugrel, a more delayed recovery of platelet function after stopping [Price et al. 2012]. Studies so far have found no sign of rebound on stopping either prasugrel or ticagrelor [Angiolillo et al. 2011;Gurbel et al. 2009, 2011; Jakubowski et al. 2011], and as their modes of action are similar this would seem rational. Reversible inhibitors of P2Y₁₂ allow more rapid return of haemostatic activity when stopped. These would be considered to be beneficial properties if urgent surgery or intervention were required, or if bleeding problems arose. However, issues of poor compliance could be more serious as a missed dose would produce intermittent reversal of platelet inhibition.

Is there a true clinical rebound?

A systematic review [Gaglia and Waksman, 2011] found most early studies to be flawed and more recent detailed analyses have cast doubt on the existence of a clinical rebound particular to clopidogrel. A retrospective analysis [Collet et al. 2009] of the CHARISMA trial data [Bhatt et al. 2006] found that in almost 3000 patients who stopped taking medication before the end of the study, there were increased rates of ischaemic events and overall mortality, but the rate was actually lower in the clopidogrel plus aspirin group compared with the placebo plus aspirin group [Collet et al. 2009]. Bleeding events were higher than in those who completed treatment, but no different between those who had been taking clopidogrel or placebo. The investigators concluded there was no evidence for a clinically detectable rebound.

Controversy still remains over the ideal duration, but the data now emerging from randomized trials demonstrate that extending the recommended time might be of no overall benefit and even detrimental [El Hayek et al. 2014; Mauri et al. 2014; Schulz-Schüpke et al. 2015; Valgimigli et al. 2013]. In the DAPT Trial [Mauri et al. 2014], the risk of stent thrombosis was reduced but all-cause mortality and the incidence of severe or moderate bleeding were significantly higher in the group that continued thienopyridine to 30 months. Interestingly the rate of stent thrombosis increased in the 3 months after stopping treatment in both the group that continued on clopidogrel and the group that had changed to placebo.

Are the reasons for stopping antiplatelet drugs important?

In most studies, the timing and the reasons for stopping antiplatelet therapy were unknown. The PARIS registry study (patterns of nonadherence to antiplatelet regimens in stented patients) [Mehran et al. 2013] followed patients for 2 years and analysed the outcomes according to prespecified reasons for stopping:

(1) ‘discontinuation’, defined as physician-recommended cessation;

(2) ‘interruption’, defined as temporary cessation of DAPT of less than 14 days due to surgical procedures;

(3) ‘disruption’, defined as withdrawal of antiplatelet treatment due to bleeding or noncompliance.

In 5031 patients, the rate of DAPT cessation by 24 months was 57.3%, mostly as physician-recommended discontinuation (40.8%), with disruption in 14.4% and interruption in 10.5%. Three-quarters of all events occurred in patients while still taking DAPT, but compared with those on treatment, the interruption and disruption group had a higher risk of MACE. In contrast, those with physician-recommended cessation had lower MACE risk than those who remained on DAPT at 24 months. The highest risk ratio in the disruption group occurred in the first 7 days after stopping. This is consistent with the study of Lemesle and colleagues who found that those stopping earliest had the highest risk of death, myocardial infarction, and stent thrombosis at 30 days [Lemesle et al. 2011].

The evidence gives reassurance that discontinuation of DAPT in low-risk patients should be considered safe, especially after 6 months from stent implantation [Franchi and Angiolillo, 2014]. Unanticipated premature disruption of treatment, however, is likely to place the patient at higher risk. Patients in this latter group are more likely to have stopped because of drug intolerance, bleeding issues or illness. Although there is no sign that clopidogrel leads to production of hyper-reactive platelets, after drug withdrawal uninhibited platelets in circulation will become activated by encountering areas of atherosclerotic vessel wall, or by increased shear stresses in narrowed arteries, or by the prothrombotic stimulus of unhealed stents.

The future of platelet testing to assess risk and guide therapy

Determining the right time to stop antiplatelet therapy in individuals remains a major issue for clinical judgement. The case for routine platelet testing at the time of PCI to guide therapy has not been supported by the recent GRAVITAS and TRIGGER-PCI trials [Price et al. 2011; Trenk et al. 2012], although in the study of Aradi and colleagues, switching those with highest on-treatment platelet reactivity from clopidogrel to prasugrel appears more promising [Aradi et al. 2014]. Testing to stratify those patients at higher risk for either bleeding or thrombotic events could be more useful [Collet and Montalescot, 2013] and there is proven value in specific situations, such as when surgery is required.

In the perioperative period, decision making on interruption of DAPT and removal of cardioprotection is complicated by the increase in both bleeding risk and hypercoagulability [Patel and Fleisher, 2014]. When it is deemed safe to do so, discontinuation of P2Y₁₂ inhibitors 5 days before cardiac surgery is advised to allow recovery of platelet function, although it is generally accepted that aspirin can be continued [Ferraris et al. 2012]. Marked individual variability in return of adequate haemostatic activity is evident however [di Dedda et al. 2014] and time to recovery is determined, inter alia, by the level of platelet reactivity before drug exposure and the extent of platelet inhibition immediately after discontinuation [Price et al. 2012]. A strong rationale is emerging for platelet testing; particularly suitable are the rapid whole blood methods requiring minimal sample preparation, such as the Multiplate (multielectrode impedance aggregometry, Roche Diagnostics GmbH, Mannheim, Germany) and the point of care test, Verify Now (Accumetrics Inc, San Diego, Ca, USA) (reviewed by Petricevic, Kong and colleagues) [Petricevic et al. 2015; Kong et al. 2015]. In addition, when surgery cannot be delayed, testing may be used to predict the need for blood products [Emeklibas et al. 2013].

Conclusion

‘Drug discontinuation effects are part of the pharmacology of a drug’ [Reidenberg, 2011] and as such are an important part of safety evaluation. The term ‘rebound’ has been applied to denote an unexpected increase in adverse clinical events at the end of a course of treatment, and has been applied to a range of drugs [Graves et al. 1997]. There has also been some misuse of the term ‘rebound’ in the literature to denote simply a return to the status quo of the predrug state. The current evidence indicates that there is nothing unusual about clopidogrel in this regard: platelet responsiveness gradually recovers to the predrug levels after stopping. The most likely explanation for post-clopidogrel ischaemic events is premature withdrawal of required protection while the damaged vessels continue to present a highly prothrombotic stimulus. A role exists for platelet testing to assist in clinical decision making.

Footnotes

Conflict of interest statement

The author declares no conflicts of interest in preparing this article.

Funding

Isobel Ford is an employee of the University of Aberdeen. The research for the writing of this review received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Angiolillo

Badimon

Saucedo

Frelinger

Michelson

Jakubowski

. (2011) A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial. Eur Heart J 32: 838–846.

Angiolillo

Fernandez-Ortiz

Bernardo

Ramirez

Sabate

Jimenez-Quevedo

. (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55: 780–784.

Aradi

Tornyos

Pintér

Vorobcsuk

Kónyi

Faluközy

. (2014) Optimizing P2Y₁₂ receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63: 1061–1070.

Bhatt

Fox

Hacke

Berger

Black

Boden

. and CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717.

Braun

Amisten

Wihlborg

Hunting

Nilsson

Erlinge

(2007) Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y₁ and the P2Y₁₂ receptor and is correlated with protein expression of P2Y₁₂. Purinergic Signal 3: 195–201.

CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.

Collet

Montalescot

(2013) Personalized antiplatelet therapy: the wrong approach? Arch Cardiovasc Dis 106: 481–486.

Collet

Montalescot

Steg

Steinhubl

Fox

. (2009) Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 102: 485–496.

COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group (2005) Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366: 1607–1621.

10.

Di Dedda

Ranucci

Baryshnikova

Castelvecchio

and Surgical and Clinical Outcome Research (SCORE) Group (2014) Thienopyridines resistance and recovery of platelet function after discontinuation of thienopyridines in cardiac surgery patients. Eur J Cardio Thorac Surg 45: 165–170.

11.

Diehl

Halscheid

Olivier

Helbing

Bode

Moser

(2011) Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 100: 765–771.

12.

Djukanovic

Todorovic

Obradovic

Njegomirovic

Zamaklar-Trifunovic

Protic

. (2014) Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. J Clin Pharm Ther 39: 69–72.

13.

Djukanovic

Todorovic

Obradovic

Zamaklar-Trifunovic

Njegomirovic

Milic

. (2011) Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events. J Pharmacol Sci 117: 12–18.

14.

El-Hayek

Messerli

Bangalore

Hong

Herzog

Benjo

. (2014) Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol 114: 236–242.

15.

Emeklibas

Kammerer

Bach

Sack

Hellstern

(2013) Preoperative hemostasis and its association with bleeding and blood component transfusion requirements in cardiopulmonary bypass surgery. Transfusion 53: 1226–1234.

16.

Ferraris

Saha

Oestreich

Song

Rosengart

Reece

. (2012) 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and non-cardiac operations. Ann Thorac Surg 94: 1761–1781.

17.

Ford

Scott

Herd

Mitchell

Williams

Brittenden

(2014) A randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. J Am Coll Cardiol 63: 233–239.

18.

Ford

Scott

Herd

Mitchell

Williams

Brittenden

(2013) Clopidogrel therapy has additional inhibitory actions on cyclo-oxygenase and thrombin receptor-mediated pathways in platelets. J Thromb Haemost 11(Suppl. 2): 495–495.

19.

Franchi

Angiolillo

(2014) Comment on cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS) study. Available at: http://www.escardio.org/communities/ACCA/publications/recommended-readings/Pages/PARIS-study.aspx (accessed 7 May 2015).

20.

Frelinger

III. Barnard

Fox

Michelson

(2010) The Platelet Activity After Clopidogrel Termination (PACT) Study. Circ Cardiovasc Interv 3: 442–449.

21.

Gaglia

Waksman

(2011) Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. Eur Heart J 32: 358–2364.

22.

Good

McGarrity

Sheehan

James

Miller

Stephens

. (2015) Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. Platelets 26: 17–24.

23.

Graves

Hanlon

Schmader

Landsman

Samsa

Pieper

. (1997) Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 157: 2205–2210.

24.

Grines

Bonow

Casey

Gardner

Lockhart

Moliterno

. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. J Am Coll Cardiol 49: 734–739.

25.

Gurbel

Bliden

Antonino

Gesheff

Jeong

Tantry

(2011) Is there a rebound after cessation of antiplatelet therapy? First comparison of irreversible vs. reversible P2Y₁₂ receptor blocker. (Abstract). J Thromb Haemost 9(Suppl. s2): O-MO-119.

26.

Gurbel

Bliden

Butler

Tantry

Geshef

Wei

. (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120: 2577–2585.

27.

Peterson

Wang

Magid

Fihn

Larsen

. (2008) Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299: 532–539.

28.

Tsai

Wang

Shetterley

Clarke

. (2010) Adverse events after stopping clopidogrel in post-acute coronary syndrome patients. Insights from a large integrated healthcare delivery system. Circ Cardiovasc Quality Outcomes 3: 303–308.

29.

Hobson

Qureshi

Banks

Curzen

(2009) Effects of clopidogrel on ‘aspirin specific’ pathways of platelet inhibition. Platelets 20: 386–390.

30.

Husted

Storey

Harrington

Emanuelsson

Cannon

(2010) Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 33: 206–212.

31.

Jakubowski

Payne

Small

Winters

(2011) Absence of ‘rebound’ platelet hyperreactivity following cessation of prasugrel. Thrombosis Haemostasis 106: 174–176.

32.

Jneid

Anderson

Wright

Adams

Bridges

Casey

(2012) 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non– ST-elevation myocardial infarction. (Updating the 2007 Guideline and Replacing the 2011 Focused Update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 60: 645–681.

33.

Kong

Trimmings

Hutchinson

Gill

Agarwal

Davidson

. (2015) Consensus recommendations for using the Multiplate(R) for platelet function monitoring before cardiac surgery. Int J Lab Hematol 37: 153–157.

34.

Lemesle

Torguson

Bonello

de Labriolle

Maluenda

Ben-Dor

. (2011) Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. Eurointervention 6: 1053–1059.

35.

Lordkipanidzé

Diodati

Pharand

(2009) Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther 123: 178–186.

36.

Lordkipanidzé

Diodati

Schampaert

Palisaitis

Pharand

(2014) Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease. Platelets: PMID: 25167467 (epub ahead of print). DOI:10.3109/09537104.2014.951318

37.

Mauri

Kereiakes

Yeh

Driscoll-Shempp

Cutlip

Steg

. (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 255–266.

38.

Mehran

Baber

Steg

Ariti

Weisz

Witzenbichler

. (2013) Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 3382: 1714–1722.

39.

Mylotte

Peace

Tedesco

Mangiacapra

Dicker

Kenny

. (2011) Clopidogrel discontinuation and platelet reactivity following coronary stenting. J Thromb Haemost 9: 24–32.

40.

Ong

McFadden

Regar

deJaegere

van Domburg

Serruys

(2005) Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45: 2088–2092.

41.

Patel

Fleisher

(2014) Aspirin, clopidogrel, and the surgeon. Adv Surg 48: 211–222.

42.

Petricevic

Kopjar

Biocina

Milicic

Kolic

Boban

. (2015) The predictive value of platelet function point-of-care tests for postoperative blood loss and transfusion in routine cardiac surgery: a systematic review. Thorac Cardiovasc Surg 63: 2–20.

43.

Pfisterer

Brunner-La Rocca

Buser

Rickenbacher

Hunziker

Mueller

. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48: 2584–2591.

44.

Price

Berger

Teirstein

Tanguay

J-F.

Angiolillo

D.J.

Spriggs

. (2011) Standard- vs high-doseclopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305: 1097–1105.

45.

Price

Walder

Baker

Heiselman

Jakubowski

Logan

. (2012) Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the Recovery trial. J Am Coll Cardiol 59: 2238–2243.

46.

Reidenberg

(2011) Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 339: 324–328.

47.

Sambu

Dent

Englyst

Warner

Leadbeater

Roderick

. (2011b) Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. Heart 97: 1661–1667.

48.

Sambu

Warner

Curzen

(2011a) Clopidogrel withdrawal: is there a rebound phenomenon? Thromb Haemost 105: 211–220.

49.

Schror

(1998) Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 3: 247–251.

50.

Schulz-Schüpke

Byrne

Ten Berg

Neumann

Han

Adriaenssens

(2015) ISAR-SAFE: a randomized, double-blind, placebocontrolled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 154(4): 620–624.

51.

Sibbing

Stegherr

Braun

Mehilli

Schulz

Seyfarth

. (2010) A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol 55: 558–565.

52.

Simon

Verstuyft

Mary-Krause

Quteineh

Druet

Meneveau

. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375.

53.

Steinhubl

Berger

Mann

III. Fry

DeLago

Wilmer

. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288: 2411–2420.

54.

Storey

Bliden

Ecob

Karunakaran

Butler

Wei

. (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb and Haemost 9: 1730–1737.

55.

Trenk

Stone

Gawaz

Kastrati

Angiolillo

Muller

. (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 59: 2159–2164.

56.

Valgimigli

Park

Kim

Park

Tricodi

. (2013) Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. Int J Cardiol 168: 2579–2587.

57.

Wallentin

Becker

Budaj

Cannon

Emanuelsson

Held

. for the PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057.

58.

Weyrich

Dixon

Pabla

Elstad

McIntyre

Prescott

. (1998) Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA 95: 5556–5561.

59.

Windecker

Kolh

Alfonso

Collet

Cremer

Falk

. (2014) 2014 ESC/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35: 2541–2619.

60.

Wiviott

Braunwald

McCabe

Montalescot

Ruzyllo

. for the TRITON–TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with Aacute coronary syndromes. N Engl J Med 357: 2001–2015.

61.

Woodward

Lowe

Francis

Rumley

Cobbe

on behalf of the CADET Study Investigators (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2: 1934–1940.

62.

Wykrzykowska

Warnholtz

de Jaeger

Curzen

Oldroyd

Collet

. (2009) Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and CRP levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 28: 410–417.

63.

Yedidya

Netzer

Vaduganathan

Solodky

Kornowski

Lev

(2012) Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents. J Thromb Thrombolysis 33: 16–21.

64.

Yusuf

Mehta

Zhao

Gersh

Commerford

Blumenthal

. (2001) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502.

Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs

Abstract

Keywords

Background

Action of clopidogrel

Duration of dual antiplatelet therapy

What happens clinically on stopping clopidogrel?

What happens to platelets when clopidogrel is withdrawn?

Platelet studies with a pretreatment baseline

Could there be adaptation of other platelet pathways to clopidogrel?

Newer P2Y12 inhibitors and platelet activity

Is there a true clinical rebound?

Are the reasons for stopping antiplatelet drugs important?

The future of platelet testing to assess risk and guide therapy

Conclusion

Footnotes

Conflict of interest statement

Funding

References

Newer P2Y₁₂ inhibitors and platelet activity